- 英文名称Pimaric Acid
- 中文名称海松酸
- IUPAC名称(1R,4aR,4bS,7S,10aR)-7-Ethenyl-1,4a,7-trimethyl-3,4,4b,5,6,9,10,10a-octahydro-2H-phenanthrene-1-carboxylic acid
- 其它别名PIMARIC ACID; 1-phenanthrenecarboxylicacid,7-ethenyl-1,2,3,4,4a,4b,5,6,7,9,10,10a-dodecahyd; 7-trimethyl-,[1theta-(1alpha,4abeta,4balpha,7beta,10aalpha)]-ro-4a; 13-alpha-methyl-13-vinylpod°Carp-8(14)-en-15-oic acid; 1-Phenanthrenecarboxylic acid, 7-ethenyl-1,2,3,4,4a,4b,5,6,7,9,10,10a-dodecahydro-1,4a,7-trimethyl-, (1R,4aR,4bS,7S,10aR)-
- CAS编号127-27-5
- MFCD编号:MFCD28369457
- FDA UNII编号:88R98Z71NI
- 分子式:C20H30O2分子量:302.45
- 产品CID: 434176
- 产品分类天然产物 → 萜类
- 相似结构搜索
- InChIKey: MHVJRKBZMUDEEV-APQLOABGSA-N
- 1S/C20H30O2/c1-5-18(2)12-9-15-14(13-18)7-8-16-19(15,3)10-6-11-20(16,4)17(21)22/h5,13,15-16H,1,6-12H2,2-4H3,(H,21,22)/t15-,16+,18+,19+,20+/m0/s1
- 计算化学: 氢键受体数2.0氢键供体数1.0可旋转键数2.0
上下游产品
CAS号64-19-7 冰醋酸 | CAS号483-87-4 1,7-二甲基菲 | CAS号514-10-3 松香酸📜Alkaline Earth Salt Of/the/ Methylsulfuric Acid置于chromium(Vi) Oxide,溶剂黄146体系中,化学反应生成海松酸
参考文献:Barton; Bruun; Soerensen,Acta Chemica Scandinavica (1947),1951,Vol. 5,P. 1356
标题:Barton; Bruun; Soerensen,Acta Chemica Scandinavica (1947),1951,Vol. 5,P. 1356
海关参考信息
- 2901210000-乙烯
2901220000-丙烯
2905121000-正丙醇
2912110000-甲醛 - 💡 提示:海关信息按照顺序优先匹配,如需确认的海关信息,请参考相关资料。
- 详情请参考:📖 海关编码查询和海关进出口税则
专利信息
专利号:US-7288671-B2
优先权日:1999-05-14
标题:Interleukin-1 and tumor necrosis factor-α modulators, synthesis of said modulators and their enantiomers and methods of using said modulators
发明人:PALLADINO MICHAEL; THEODORAKIS EMMANUEL A
权利人:UNIV CALIFORNIA
摘要:Novel compounds are disclosed that have the following chemical structures, and prodrug esters and acid-addition salts thereof, that are useful as Interleukin-1 and Tumor Necrosis Factor-α modulators, and thus are useful in the treatment of various diseases. n nwherein the R groups are defined as follows: if any R 3 -R 5 , R 7 , R 8 , R 11 -R 13 is not hydrogen, R 2 or R 6 or R 9 is not methyl, or R 10 is not CH 2 , then R 1 is selected from the group consisting of hydrogen, a halogen, COOH, C 1 -C 12 carboxylic acids, C 1 -C 12 acyl halides, C 1 -C 12 acyl residues, C 1 -C 12 esters, C 1 -C 12 secondary amides, (C 1 -C 12 )(C 1 -C 12 ) tertiary amides, (C 1 -C 12 )(C 1 -C 12 ) cyclic amides, (C 1 -C 12 ) amines, C 1 -C 12 alcohols, (C 1 -C 12 )(C 1 -C 12 ) ethers, C 1 -C 12 alkyls, C 1 -C 12 substituted alkyls, C 2 -C 12 alkenyls, C 2 -C 12 substituted alkenyls, and C 5 -C 12 aryls. If all R 3 -R 5 , R 7 , R 8 , R 11 -R 13 are hydrogen, R 2 , R 6 , and R 9 are each methyl, and R 10 is CH 2 , then R 1 is selected from hydrogen, a halogen, C 1 -C 12 carboxylic acids, C 1 -C 12 acyl halides, C 1 -C 12 acyl residues, C 2 -C 12 esters, C 2 -C 12 secondary amides, (C 1 -C 12 )(C 1 -C 12 ) tertiary amides, C 2 -C 12 alcohols, (C 1 -C 12 )(C 1 -C 12 ) ethers other than methyl-acetyl ether, C 2 -C 12 alkyls, C 1 -C 12 substituted alkyls, C 2 -C 12 alkenyls, C 2 -C 12 substituted alkenyls, and C 2 -C 12 aryls. R 2 and R 9 are each separately selected from hydrogen, a halogen, C 1 -C 12 alkyl, C 1 -C 12 substituted alkyls, C 2 -C 12 alkenyl, C 2 -C 12 substituted alkenyl, C 2 -C 12 alkynyl, C 1 -C 12 acyl, C 1 -C 12 alcohol, and C 5 -C 12 aryl. R 3 -R 5 , R 7 , R 8 , and R 11 -R 13 are each separately selected from hydrogen, a halogen, C 1 -C 12 alkyl, C 1 -C 12 substituted alkyls, C 2 -C 12 alkenyl, C 2 -C 12 substituted alkenyl, C 2 -C 12 alkynyl, and C 5 -C 12 aryl. R 6 is selected from hydrogen, a halogen, C 1 -C 12 alkyl, C 1 -C 12 substituted alkyls, C 2 -C 12 alkenyl, C 2 -C 12 substituted alkenyl, and C 2 -C 12 alkynyl. R 10 is selected from hydrogen, a halogen, CH 2 , C 1 -C 6 alkyl, C 1 -C 6 substituted alkyl, C 2 -C 6 alkenyl, C 2 -C 6 substituted alkenyl, C 1 -C 12 alcohol, and C 5 -C 12 aryl. Pharmaceutical compositions comprising, and uses of, therapeutically effective amounts of the aove compounds and their prodrug esters, and a pharmaceutically acceptable carrier, are also disclosed, and are useful as, for example, anti-inflammatory analgesics, in treating immune disorders, as anti-cancer and anti-tumor agents, and in the treatment of cardiovascular disease, skin redness, and viral infection. Completely synthetic and semi-synthetic methods of making these compounds and their analogs, are also disclosed.
专利号:US-7119223-B2
优先权日:1999-05-14
标题:Interleukin-1 and tumor necrosis factor-α modulators, synthesis of said modulators and their enantiomers and methods of using said modulators
专利号:JP-2012211162-A
优先权日:1999-05-14
标题 :Novel interleukin-1 and tumor necrosis factor-α modulator, synthesis of the modulator, and method of using the modulator
专利号:US-2006252832-A1
优先权日:1999-05-14
标题 :Novel interleukin-1 and tumor necrosis factor-alpha modulators, synthesis of said modulators and their enantiomers and methods of using said modulators
专利号:CN-101365674-A
优先权日:2005-07-21
标题:Modulators of interleukin-1 and tumor necrosis factor alpha, synthesis of the modulators and methods of using the modulators
专利号:ES-2295031-T3
优先权日:1999-05-14
标 题:NEW MODULATORS OF INTERLEUCINE-1 AND TUMOR NECROSIS FACTOR, SYNTHESIS OF SUCH MODULATORS AND METHODS OF USE OF SUCH MODULATORS.